Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Exclusion Criteria

• •Patients who have had chemotherapy, rituximab, or radiotherapy within 4 weeks, or radioimmunotherapy within 8 weeks prior to entering the study
• •Receiving any other investigational agent
• •Known brain metastases
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to Clofarabine
• •Systemic fungal, bacterial, viral, or other infection not controlled
• •Pregnant or lactating
• •Prior history of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for over one year
• •Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •Prior allogeneic stem cell transplantation